The Supplementary Effects of the Extract of Agaricus Blazei Murril on Type II Diabetes Mellitus (DM)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00131287

Enrollment

108

Registered

2005-08-18

Start date

2005-07-31

Completion date

2006-12-31

Last updated

2010-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type II

Keywords

Agaricus Blazei Murill, type II DM, insulin index

Brief summary

The purpose of this study is to examine whether the extract of the Agaricus blazei Murill mushroom is effective in the supplementary treatment of type II DM patients.

Detailed description

The researchers have the animal model that the extract of the Agaricus blazei Murill mushroom is effective in the treatment of type II DM mice conducted on 2002. The dose effects were also found. The researchers conducted the pilot study also showing the same effects in 2003. So the researchers designed this trial. The elixir of the Agaricus blazei Murill mushroom is popular in Taiwan for chronic diseases, such as type II DM.

Interventions

DRUGExtract of Agaricus blazei Murill

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Type II DM * Age 20-75 years old * Treat with Gliclazide and Metformin * Signed informed consent

Exclusion criteria

* GOT/GPT \>80/80 * Creatinine \> 2.0 * Lactating or pregnant women

Design outcomes

Primary

Measure	Time frame
Percent reduction of glycated hemoglobin (HAb1C) and insulin resistance(HOMA-IR)	—

Secondary

Measure	Time frame
Glucose, cholesterol, triglyceride, leptin, adiponectin comparisons	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026